Remove Capital Raising Remove Portfolio Management Remove Private Equity
article thumbnail

Intrepid Capital Advisory Update – A View From the Trenches

Intrepid Banker Insights

We’re constantly monitoring our portfolio companies’ ability to pass on price increases, particularly as consumers’ wallets come under immense pressure.” – Portfolio Manager, private credit fund “There’s no such thing as a free lunch. The Fed Funds Rate sits at 4%, and SOFR is expected to peak at 4.8% in Q2 2023.

article thumbnail

How Merchant Banks Help Businesses Grow and Succeed

Razorpay

Portfolio Management Merchant banking companies provide portfolio management services to high -net-worth individuals and corporate investors. These services include a selection of securities, portfolio monitoring and review, advice on the rationalization of portfolios, and tax planning.

Bank 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What is Private Banking and How Does It Work?

Razorpay

This consolidated approach simplifies financial management and helps clients achieve their long-term objectives. Exclusive Investment Opportunities Private banking clients gain access to investment products and opportunities not available to the general public, such as: Private equity and hedge funds.

Bank 52
article thumbnail

Event-Driven Hedge Funds: The Best Home for Bankers Turned Investors?

Mergers and Inquisitions

Special Situations – These funds focus on companies that are spinning off or divesting divisions, reorganizing, or otherwise going through more unusual changes (not just simple acquisitions or capital raises). Even corporate development or private equity might be possible, depending on what you did before joining your current fund.

Funds 64
article thumbnail

Biotech Hedge Funds: A Match Made in Heaven

Mergers and Inquisitions

In technology, as a startup keeps raising capital, it normally does so at gradually higher valuations as its customers, users, and revenue grow. But in biotech, companies valuations often remain close to their total capital raised until much later in the process (i.e.,

Funds 64